Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial

AIMS: To assess the pharmacokinetic and pharmacodynamic profile of a single dose of empagliflozin in young people with Type 2 diabetes to identify the appropriate doses for further paediatric development. METHODS: We conducted a single‐dose, open‐label, randomized, parallel‐group study with empaglif...

Descripción completa

Detalles Bibliográficos
Autores principales: Laffel, L. M. B., Tamborlane, W. V., Yver, A., Simons, G., Wu, J., Nock, V., Hobson, D., Hughan, K. S., Kaspers, S., Marquard, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099360/
https://www.ncbi.nlm.nih.gov/pubmed/29655290
http://dx.doi.org/10.1111/dme.13629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099360/
https://www.ncbi.nlm.nih.gov/pubmed/29655290
http://dx.doi.org/10.1111/dme.13629

Ejemplares similares